Xspray Pharma Q4 2024: In anticipation of an eventful year - Redeye

Redeye provides an update on Xspray Pharma following its year-end report, which revealed no major surprises. Material events are anticipated in the coming months, with the NDA resubmission for Dasynoc on track for March/April and the XS003 NDA submission expected in H1 2025.

Länk till analysen i sin helhet: https://www.redeye.se/research/1073324/xspray-pharma-q4-2024-in-anticipation-of-an-eventful-2025?utm_source=finwire&utm_medium=RSS